Diagnostic and therapeutic monitoring value of serum platelet-derived growth factor BB level in non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the clinical significance of the serum platelet-derived growth factor BB (PDGF-BB) level in the diagnosis and treatment monitoring of non-small cell lung cancer (NSCLC) patients.Methods:Serum samples of 111 NSCLC patients in Xuzhou Cancer Hospital of Jiangsu Province and 105 healthy controls from Outpatients Department of Nanjing Yian Medical Examination Center between October 2014 and December 2017 were collected. Luminex assay was used to determine PDGF-BB level in serum samples of NSCLC patients and the healthy controls as well as patients after platinum chemotherapy. Receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of serum PDGF-BB level in patients with NSCLC, and the relationship of serum PDGF-BB level with clinicopathological features of NSCLC patients and platinum chemotherapy and effect was analyzed.Results:Compared to the healthy controls, serum PDGF-BB level was decreased in NSCLC patients [(54±24) ng/ml vs. (125±61) ng/ml, t = 11.09, P < 0.01], and the area under the ROC of serum PDGF-BB level on the diagnosis of NSCLC was 0.890. There were no significant differences in serum PDGF-BB level among NSCLC patients with different gender, age or lymph node metastasis (all P > 0.05); the serum PDGF-BB level in patients with high TNM stage was lower than that in patients with low TNM stage, and the serum PDGF-BB level in patients with low differentiation degree was lower than that in patients with high differentiation degree (all P < 0.05). Serum PDGF-BB level was continued to decrease in NSCLC patients after treatment with platinum-based chemotherapy. Conclusion:Serum PDGF-BB level of NSCLC patients is decreased, and it has a certain clinical significance in the early diagnosis of NSCLC.